SAN ANTONIO, Texas, May 19, 2026
Valion Bio, Inc. has announced a high-level joint engagement with senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA) regarding the company’s lead innate immunotherapeutic candidate, Entolimod, for the treatment of Acute Radiation Syndrome (ARS). The strategic briefing focused on the therapeutic’s potential role as a next-generation medical countermeasure against radiological threats, including interest in the development of an oral formulation capable of supporting rapid field deployment and national stockpile integration.
The meeting, held on May 14, 2026, represented Valion Bio’s second senior-level engagement with Department of War officials within weeks, following an earlier Pentagon briefing conducted on April 28. According to the company, the joint participation of BARDA and defense leadership highlights increasing U.S. government attention toward scalable biodefense solutions amid rising geopolitical concerns surrounding radiological preparedness and national security resilience.
Valion Bio executives stated that the growing cross-agency interest reflects recognition of Entolimod’s differentiated mechanism and operational flexibility compared with currently stockpiled radiation countermeasures. Industry experts believe the discussions may signal strengthening federal interest in advanced radiation therapeutics capable of addressing both civilian emergency preparedness and military deployment scenarios.
Entolimod Targets Both Bone Marrow and GI Radiation Damage
Entolimod is a novel Toll-like receptor 5 (TLR5) agonist engineered to activate NF-κB signaling pathways, stimulating protective immune and tissue recovery responses following exposure to ionizing radiation. Unlike traditional radiation countermeasures that focus primarily on hematopoietic recovery, Entolimod is designed to protect both bone marrow and gastrointestinal tissues, two of the most critical systems affected during severe radiation exposure.
Advertisement
The company emphasized that gastrointestinal injury frequently becomes the primary limiting factor for survival at high radiation doses, creating substantial unmet need for therapies capable of broader tissue protection. Current stockpiled therapies such as Neupogen®, Neulasta®, and Leukine® primarily target hematopoietic recovery alone.
Valion Bio is currently advancing both injectable and oral transmucosal formulations of Entolimod. Government stakeholders reportedly expressed strong interest in the oral version due to its potential advantages in mass-casualty situations, where rapid administration, portability, and simplified logistics become essential operational requirements.
Researchers believe orally deployable countermeasures may significantly improve emergency response capabilities during radiological incidents involving large civilian populations or military personnel operating in high-risk environments.
Government Support Strengthens Biodefense Development Pathway
Valion Bio confirmed that more than $140 million has been invested in the Entolimod development program to date, including approximately $35.6 million in non-dilutive federal funding. The therapy has already been evaluated across 42 non-human primate studies and administered to approximately 300 human subjects, generating extensive safety and efficacy data supporting continued advancement under the FDA’s Animal Rule regulatory pathway.
The FDA Animal Rule allows approval of therapies intended for conditions where traditional human efficacy trials are not ethical or feasible, particularly in biodefense and radiological emergency settings. Valion Bio stated that Entolimod has already received both Fast Track and Orphan Drug designations from the FDA for acute radiation syndrome.
The company also highlighted ongoing collaboration with multiple U.S. government agencies including BARDA, the National Institute of Allergy and Infectious Diseases (NIAID), and the Defense Threat Reduction Agency (DTRA). Entolimod has additionally been selected for participation in the Department of War’s Tech Watch program, further strengthening its position within the biodefense ecosystem.
Healthcare and defense analysts note that recent geopolitical instability and increasing concerns surrounding radiological preparedness have intensified federal investment interest in advanced medical countermeasure technologies capable of rapid deployment during national emergencies.
Biodefense Innovation Expands Across Bio-Pharma Sector
Valion Bio, formerly known as Tivic Health Systems, continues positioning itself as a late-stage biotechnology company focused on innate immune pathway activation and cytoprotective therapeutics. In addition to Entolimod, the company is advancing Entolasta, a next-generation TLR5 agonist being evaluated for broader therapeutic applications including oncology supportive care.
Industry experts believe biodefense-focused biotechnology innovation will continue accelerating as governments worldwide strengthen preparedness strategies against radiological threats, emerging infectious diseases, and national security-related health emergencies.
Valion Bio stated that its objective remains advancing Entolimod into a fully deployable national capability capable of supporting mass-casualty response, military readiness, and public health emergency preparedness. Analysts expect continued federal engagement and regulatory progress to remain closely monitored as the company advances toward a future Biologics License Application (BLA) submission under FDA regulatory frameworks.
Source: Valion Bio press release
